Novel action of the chalcone isoliquiritigenin as a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor: Potential therapy for cholera and polycystic kidney disease

Journal of Pharmacological Sciences

Volumn 118, Issue 1, 2012, Pages 82-91

  Muanprasat, Chatchai ^a   Sirianant, Lalida ^b   Soodvilai, Sunhapas ^a   Chokchaisiri, Ratchanaporn ^c   Suksamrarn, Apichart ^c   Chatsudthipong, Varanuj ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Mahidol University   (Thailand)

^c RAMKHAMHAENG UNIVERSITY   (Thailand)

Author keywords

Chalcone; Cholera; Cystic fibrosis transmembrane conductance regulator (CFTR); Isoliquiritigenin; Polycystic kidney disease

Indexed keywords

CALCIUM ION; CHLORIDE CHANNEL; CHLORIDE ION; CHOLERA TOXIN; CYCLIC AMP; ISOLIQUIRITIGENIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN; CELL VIABILITY; CHOLERA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; INTESTINE EPITHELIUM CELL; INTESTINE FLUID; KIDNEY POLYCYSTIC DISEASE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING;

EID: 84856570690     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11153FP     Document Type: Article

References (37)

1. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev. 2002;82:245-289. (Pubitemid 34654220)
2. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol. 2000;62:535-572. (Pubitemid 30618274)
3. -transport. J Biol Chem. 2010;285:7165-7175.
4. Vallon V, Grahammer F, Volkl H, Sandu CD, Richter K, Rexhepaj R, et al. KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci U S A. 2005;102:17864-17869. (Pubitemid 41803588)
5. Hoque KM, Woodward OM, van Rossum DB, Zachos NC, Chen L, Leung GP, et al. Epac1 mediates protein kinase A-independent mechanism of forskolin-activated intestinal chloride secretion. J Gen Physiol. 2010;135:43-58.
6. - secretion. Acta Physiol (Oxf). 2007;189:251-258.
7. - secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci. 2011;56:339-351.
8. - secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology. 2009; 137:976-985.
9. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet. 2004;363(9404):223-233. (Pubitemid 38114723)
10. Field M. Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest. 2003;111:931-943. (Pubitemid 36397466)
11. Thiagarajah JR, Verkman AS. New drug targets for cholera therapy. Trends Pharmacol Sci. 2005;26:172-175. (Pubitemid 40432650)
12. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol. 2004;124:125-137. (Pubitemid 39038187)
13. Wongsamitkul N, Sirianant L, Muanprasat C, Chatsudthipong V. A plant-derived hydrolysable tannin inhibits CFTR chloride channel: a potential treatment of diarrhea. Pharm Res. 2010;27:490-497.
14. Sullivan LP, Wallace DP, Grantham JJ. Epithelial transport in polycystic kidney disease. Physiol Rev. 1998;78:1165-1191. (Pubitemid 28491952)
15. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 2004;66:964-973. (Pubitemid 39120999)
16. Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS. Smallmolecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:1300-1310.
17. Yadav VR, Prasad S, Sung B, Aggarwal BB. The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int Immunopharmacol. 2011;11:295-309.
18. Kim DC, Choi SY, Kim SH, Yun BS, Yoo ID, Reddy NR, et al. Isoliquiritigenin selectively inhibits H(2) histamine receptor signaling. Mol Pharmacol. 2006;70:493-500. (Pubitemid 44092310)
19. Yamamoto S, Aizu E, Jiang H, Nakadate T, Kiyoto I, Wang JC,et al. The potent anti-tumor-promoting agent isoliquiritigenin. Carcinogenesis. 1991;12:317-323.
20. Tawata M, Aida K, Noguchi T, Ozaki Y, Kume S, Sasaki H, et al. Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur J Pharmacol. 1992;212:87-92.
21. Teke GN, Kuiate JR, Kuete V, Teponno RB, Tapondjou LA, Vilarem G. Antidiarrheal activity of extracts and compound from Trilepisium madagascariense stem bark. Indian J Pharmacol. 2010;42:157-163.
22. Racusen LC, Binder HJ. Ricinoleic acid stimulation of active anion secretion in colonic mucosa of the rat. J Clin Invest. 1979;63:743-749. (Pubitemid 9167043)
23. Gaginella TS, Chadwick VS, Debongnie JC, Lewis JC, Phillips SF. Perfusion of rabbit colon with ricinoleic acid: dose-related mucosal injury, fluid secretion, and increased permeability. Gastroenterology. 1977;73:95-101. (Pubitemid 8143348)
24. Chokchaisiri R, Suaisom C, Sriphota S, Chindaduang A, Chuprajob T, Suksamrarn A. Bioactive flavonoids of the flowers of Butea monosperma. Chem Pharm Bull (Tokyo). 2009;57:428-432.
25. Bebok Z, Tousson A, Schwiebert LM, Venglarik CJ. Improved oxygenation promotes CFTR maturation and trafficking in MDCK monolayers. Am J Physiol Cell Physiol. 2001;280:C135-C145.
26. - secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int. 2004;66:1926-1938.
27. Cao Y, Wang Y, Ji C, Ye J. Determination of liquiritigenin and isoliquiritigenin in Glycyrrhiza uralensis and its medicinal preparations by capillary electrophoresis with electrochemical detection. J Chromatogr A. 2004;1042:203-209. (Pubitemid 38813371)
28. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, et al. Thiazolidinone CFTR inhibitor identified by highthroughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest. 2002;110:1651-1658. (Pubitemid 35424243)
29. Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS. Prevention of toxin-induced intestinal ion and fluid secretion by a smallmolecule CFTR inhibitor. Gastroenterology. 2004;126:511-519. (Pubitemid 38182308)
30. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov. 2009;8:153-171.
31. Muanprasat C, Kaewmokul S, Chatsudthipong V. Identification of new small molecule inhibitors of cystic fibrosis transmembrane conductance regulator protein: in vitro and in vivo studies. Biol Pharm Bull. 2007;30:502-507. (Pubitemid 46355933)
32. Tradtrantip L, Sonawane ND, Namkung W, Verkman AS. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem. 2009;52:6447-6455.
33. Chen G, Zhu L, Liu Y, Zhou Q, Chen H, Yang J. Isoliquiritigenin, a flavonoid from licorice, plays a dual role in regulating gastrointestinal motility in vitro and in vivo. Phytother Res. 2009;23:498-506.
34. Sato Y, He JX, Nagai H, Tani T, Akao T. Isoliquiritigenin, one of the antispasmodic principles of Glycyrrhiza ularensis roots, acts in the lower part of intestine. Biol Pharm Bull. 2007;30:145-149. (Pubitemid 46066335)
35. Fung C, Ellis M, Bornstein JC. Luminal cholera toxin alters motility in isolated guinea-pig jejunum via a pathway independent of 5-HT(3) receptors. Front Neurosci. 2010;4:162.
36. Choi SH, Kim YW, Kim SG. AMPK-mediated GSK3beta inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress. Biochem Pharmacol. 2010;79:1352-1362.
37. Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011;108:2462-2467.